Discover how the St. Jude Lifetime Cohort Study uncovered community-level factors influencing chronic health condition risks, and how that can improve care.

Explore new research that created better patient-derived models of the pediatric cancer’s high-risk variants and uncovered how to identify mesenchymal cells.

Explore a shared vulnerability in two of the childhood brain tumor's types, opening opportunities for targeted therapies in patients with high-risk disease.

Explore new St. Jude research finding how removing the immune response “brake” gene ZMYND8 led to better control of solid tumors and chronic viral infections.

Meet Emily Tonorezos, MD, MPH, the incoming St. Jude Division of Cancer Survivorship director, and learn about her prior research and plans for the program.

Join us November 16-18, 2026 for a symposium that will enrich the collaborative data science culture by sharing and brainstorming ways to gain the most valuable scientific knowledge from biomedical da...

SAGES1, a clinical trial testing a gene editing approach sickle cell disease is significant because every aspect of the trial occurs on the St. Jude campus.

See how a machine-learning drug discovery platform for ultra-large virtual screenings called AdaptiveFlow guides the rational selection for deeper exploration

Discover how St. Jude researchers uncovered how regional differences in the developing brain shape diffuse midline glioma formation.

Explore a cellular immunotherapy that controlled relapsed bone cancer and prevented metastasis in model systems, setting the foundation for a clinical trial.

The Board of Governors announce Charles W.M. Roberts, MD, PhD, as the next president and CEO of St. Jude. Roberts will step into the role effective January 1, 2027.